echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Novartis' first-in-class drug Iptacopan to be included in breakthrough therapy

    Novartis' first-in-class drug Iptacopan to be included in breakthrough therapy

    • Last Update: 2022-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 14, CDE's official website showed that Novartis' LNP023 capsules are intended to be included in the breakthrough therapy program for C3 glomerulopathy (C3G)


    Official website public information

    From: CDE official website

    Iptacopan (LNP023) is a first-in-class, orally targeted factor B inhibitor that targets the alternative complement pathway, a key driver of complement-related renal diseases (CDRDs)


    From: Novartis R&D Day 2021

    Iptacopan is currently in multi-indication development


    From: Novartis R&D Day 2021

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.